| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 147, 815-822, Copyright © 1995 by American Society for Investigative Pathology
REGULAR ARTICLES |
XC Xu, AK el-Naggar and R Lotan
Department of Tumor Biology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Carcinoma of the thyroid gland, the most frequently diagnosed endocrine malignancy, is often associated with early regional metastases. With the exception of papillary carcinoma, distinguishing benign from malignant thyroid neoplasms in the absence of metastatic disease is difficult. Recently, the vertebrate lectins galectin-1 and galectin-3 have been implicated in the regulation of cellular growth, differentiation, and malignant transformation of a variety of tissues. To determine whether these galectins have a role in thyroid neoplasia, we analyzed 32 specimens from thyroid malignancies (16 papillary, 7 follicular, 8 medullary carcinomas, and 1 metastasis to lymph node), 10 benign thyroid adenomas, 1 nodular goiter, and 33 specimens from adjacent normal thyroid tissue for the expression of galectin-1 and galectin-3 with immunohistochemical and immunoblotting techniques utilizing anti-galectin antibodies. All thyroid malignancies of epithelial origin (ie, papillary and follicular carcinomas) and a metastatic lymph node from a papillary carcinoma expressed high levels of both galectin-1 and galectin-3. The medullary thyroid carcinomas, which are of parafollicular C cell origin, showed a weaker and variable expression of these galectins. In contrast, neither benign thyroid adenomas nor adjacent normal thyroid tissue expressed galectin-1 or galectin-3. These results suggest that galectin-1 and galectin-3 may be associated with malignant transformation of thyroid epithelium and may potentially serve as markers for distinguishing benign thyroid adenomas from differentiated thyroid carcinomas.
This article has been cited by other articles:
 |
|
 |
|
  Y. Y Liu, H. Morreau, J. Kievit, J. A Romijn, N. Carrasco, and J. W Smit Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma Eur. J. Endocrinol., March 1, 2008; 158(3): 375 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. A. Biron, M. M. Iglesias, M. F. Troncoso, M. Besio-Moreno, Z. J. Patrignani, O. P. Pignataro, and C. Wolfenstein-Todel Galectin-1: biphasic growth regulation of Leydig tumor cells Glycobiology, September 1, 2006; 16(9): 810 - 821. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Castro and H. Gharib Continuing Controversies in the Management of Thyroid Nodules Ann Intern Med, June 7, 2005; 142(11): 926 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Saggiorato, R De Pompa, M Volante, S Cappia, F Arecco, A P Dei Tos, F Orlandi, and M Papotti Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application Endocr. Relat. Cancer, June 1, 2005; 12(2): 305 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. H. Ruebel, L. Jin, X. Qian, B. W. Scheithauer, K. Kovacs, N. Nakamura, H. Zhang, A. Raz, and R. V. Lloyd Effects of DNA Methylation on Galectin-3 Expression in Pituitary Tumors Cancer Res., February 15, 2005; 65(4): 1136 - 1140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Torres-Cabala, A. Panizo-Santos, H. C. Krutzsch, H. Barazi, M. Namba, M. Sakaguchi, D. D. Roberts, and M. J. Merino Differential Expression of S100C in Thyroid Lesions International Journal of Surgical Pathology, April 1, 2004; 12(2): 107 - 115. [Abstract] [PDF]
|
|
|
|
 |
|
 C E Anderson and K M McLaren Best Practice No 171: Best practice in thyroid pathology J. Clin. Pathol., June 1, 2003; 56(6): 401 - 405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Nikiforova, R. A. Lynch, P. W. Biddinger, E. K. Alexander, G. W. Dorn II, G. Tallini, T. G. Kroll, and Y. E. Nikiforov RAS Point Mutations and PAX8-PPAR{gamma} Rearrangement in Thyroid Tumors: Evidence for Distinct Molecular Pathways in Thyroid Follicular Carcinoma J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2318 - 2326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Riss, L. Jin, X. Qian, J. Bayliss, B. W. Scheithauer, W. F. Young Jr., S. Vidal, K. Kovacs, A. Raz, and R. V. Lloyd Differential Expression of Galectin-3 in Pituitary Tumors Cancer Res., May 1, 2003; 63(9): 2251 - 2255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Savin, D. S. Cvejic, and M. M. Jankovic Expression of Galectin-1 and Galectin-3 in Human Fetal Thyroid Gland J. Histochem. Cytochem., April 1, 2003; 51(4): 479 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. K. Mandal and C. Mukhopadhyay Binding free energy calculations of galectin-3-ligand interactions Protein Eng. Des. Sel., December 1, 2002; 15(12): 979 - 986. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. J. Bernet, J. Anderson, Y. Vaishnav, B. Solomon, C. F. Adair, M. Saji, K. D. Burman, H. B. Burch, and M. D. Ringel Determination of Galectin-3 Messenger Ribonucleic Acid Overexpression in Papillary Thyroid Cancer by Quantitative Reverse Transcription-Polymerase Chain Reaction J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4792 - 4796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Martins, S. E. Matsuo, K. N. Ebina, M. A. V. Kulcsar, C. U. M. Friguglietti, and E. T. Kimura Galectin-3 Messenger Ribonucleic Acid and Protein Are Expressed in Benign Thyroid Tumors J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4806 - 4810. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Piantelli, S. Iacobelli, G. Almadori, M. Iezzi, N. Tinari, C. Natoli, G. Cadoni, L. Lauriola, and F. O. Ranelletti Lack of Expression of Galectin-3 Is Associated With a Poor Outcome in Node-Negative Patients With Laryngeal Squamous-Cell Carcinoma J. Clin. Oncol., September 15, 2002; 20(18): 3850 - 3856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Yu, R. L. Finley Jr., A. Raz, and H.-R. C. Kim Galectin-3 Translocates to the Perinuclear Membranes and Inhibits Cytochrome c Release from the Mitochondria. A ROLE FOR SYNEXIN IN GALECTIN-3 TRANSLOCATION J. Biol. Chem., May 3, 2002; 277(18): 15819 - 15827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Rabinovich, N. Rubinstein, and L. Fainboim Unlocking the secrets of galectins: a challenge at the frontier of glyco-immunology J. Leukoc. Biol., May 1, 2002; 71(5): 741 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Almkvist, C. Dahlgren, H. Leffler, and A. Karlsson Activation of the Neutrophil Nicotinamide Adenine Dinucleotide Phosphate Oxidase by Galectin-1 J. Immunol., April 15, 2002; 168(8): 4034 - 4041. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. K. Song, T. R. Billiar, and Y. J. Lee Role of Galectin-3 in Breast Cancer Metastasis : Involvement of Nitric Oxide Am. J. Pathol., March 1, 2002; 160(3): 1069 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Saggiorato, S. Cappia, P. De Giuli, A. Mussa, G. Pancani, P. Caraci, A. Angeli, and F. Orlandi Galectin-3 as a Presurgical Immunocytodiagnostic Marker of Minimally Invasive Follicular Thyroid Carcinoma J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5152 - 5158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.-K. Moon, Y. J. Lee, P. Battle, J. M. Jessup, A. Raz, and H.-R. C. Kim Galectin-3 Protects Human Breast Carcinoma Cells against Nitric Oxide-Induced Apoptosis : Implication of Galectin-3 Function during Metastasis Am. J. Pathol., September 1, 2001; 159(3): 1055 - 1060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. HARVEY, Y. ZHANG, F. LANDRY, C. MILLER, and J. W. SMITH Insights into a plasma membrane signature Physiol Genomics, April 2, 2001; 5(3): 129 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. O. Berberat, H. Friess, L. Wang, Z. Zhu, T. Bley, L. Frigeri, A. Zimmermann, and M. W. Büchler Comparative Analysis of Galectins in Primary Tumors and Tumor Metastasis in Human Pancreatic Cancer J. Histochem. Cytochem., April 1, 2001; 49(4): 539 - 549. [Abstract] [Full Text]
|
|
|
|
 |
|
 Y. Honjo, H. Inohara, S. Akahani, T. Yoshii, Y. Takenaka, J.-i. Yoshida, K. Hattori, Y. Tomiyama, A. Raz, and T. Kubo Expression of Cytoplasmic Galectin-3 as a Prognostic Marker in Tongue Carcinoma Clin. Cancer Res., December 1, 2000; 6(12): 4635 - 4640. [Abstract] [Full Text]
|
|
|
|
 |
|
 H.-M. Lin, B.-K. Moon, F. Yu, and H.-R. C. Kim Galectin-3 mediates genistein-induced G2/M arrest and inhibits apoptosis Carcinogenesis, November 1, 2000; 21(11): 1941 - 1945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Sano, D. K. Hsu, L. Yu, J. R. Apgar, I. Kuwabara, T. Yamanaka, M. Hirashima, and F.-T. Liu Human Galectin-3 Is a Novel Chemoattractant for Monocytes and Macrophages J. Immunol., August 15, 2000; 165(4): 2156 - 2164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Nangia-Makker, Y. Honjo, R. Sarvis, S. Akahani, V. Hogan, K. J. Pienta, and A. Raz Galectin-3 Induces Endothelial Cell Morphogenesis and Angiogenesis Am. J. Pathol., March 1, 2000; 156(3): 899 - 909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Hsu, R.-Y. Yang, Z. Pan, L. Yu, D. R. Salomon, W.-P. Fung-Leung, and F.-T. Liu Targeted Disruption of the Galectin-3 Gene Results in Attenuated Peritoneal Inflammatory Responses Am. J. Pathol., March 1, 2000; 156(3): 1073 - 1083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gasbarri, M. P. Martegani, F. Del Prete, T. Lucante, P. G. Natali, and A. Bartolazzi Galectin-3 and CD44v6 Isoforms in the Preoperative Evaluation of Thyroid Nodules J. Clin. Oncol., November 1, 1999; 17(11): 3494 - 3502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.-Y. Yang, D. K. Hsu, L. Yu, J. Ni, and F.-T. Liu Cell Cycle Regulation by Galectin-12, a New Member of the Galectin Superfamily J. Biol. Chem., June 1, 2001; 276(23): 20252 - 20260. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
